Membrane protein drug targets represent a significant challenge for high-resolution three-dimensional structure determination limiting the discovery and development of novel medicines. leadXpro AG, a company at PARK INNOVAARE, successfully tackles the membrane protein structure identification challenge to advance the drug discovery process and bring better drugs to the market.
